Jens Juul Holst

Jens Juul Holst

Professor


  1. Published

    Changes in serum leptin do not correlate to total fat mass in patients with thyrotoxicosis. / Zimmermann-Belsing, T.; Dreyer, M.; Holst, J.J.; Feldt-Rasmussen, U.

    In: J. Endocrinol., No. 49, 1998, p. 589-595.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Published

    Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. / Wojdemann, M.; Wettergren, A.; Hartmann, Bolette; Holst, J.J.

    In: Scandinavian Journal of Gastroenterology, No. 33, 1998, p. 828-832.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Inhibition of human gastric lipase secretion by glucagon-like peptide-1. / Wojdemann, M.; Wettergren, A.; Sternby, B.; Holst, J.J.; Larsen, S.; Rehfeld, J.F.; Olsen, O.

    In: Dig. Dis. Sci., No. 43, 1998, p. 799-805.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients. / Willms, B.; Idowu, K.; Holst, J.J.; Creutzfeldt, W.; Nauck, M.A.

    In: Exp. Clin. Endocrinol. Diabetes, No. 106, 1998, p. 103-107.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    The inhibitory effect of glucagon-like peptide-1 (7-36) amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36) amide. / Wettergren, A.; Wojdemann, M.; Holst, J.J.

    In: Peptides, No. 19, 1998, p. 877-882.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans. / Wettergren, A.; Pridal, L.; Wöjdemann, M.; Holst, J.J.

    In: Regul. Pept., No. 77, 1998, p. 83-88.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. / Wettergren, A.; Wojdemann, M.; Holst, J.J.

    In: Am. J. Physiol., No. 275, 1998, p. G984-G992.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: Effect mediated through central or enteric nervous mechanisms. / Tolessa, T.; Gutniak, M.K.; Holst, J.J.; Efendic, S.; Hellstrom, P.M.

    In: Dig. Dis. Sci., No. 43, 1998, p. 2284-2290.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. / Tolessa, T.; Gutniak, M.K.; Holst, J.J.; Efendic, S.; Hellstrom, P.M.

    In: J. Clin. Invest., No. 102, 1998, p. 764-774.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. / Toft-Nielsen, M; Madsbad, Sten; Holst, Jens Juul.

    In: Diabetologia, Vol. 41, No. 10, 1998, p. 1180-1186.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 4 Next

ID: 4207